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1. Introduction 
The application of nanotechnology for diagnostic or therapeutic application is 
called nanomedicine (Jain & Stylianopoulos 2010). Nanomedicine is an 
interdisciplinary field in which biology, medicine, chemistry, physics and other 
disciplines are brought together in order to develop nanomaterials suitable for 
biomedical application (Wicki et al. 2015). Nanoparticle size (in the range from a 
few nanometers to a few hundred nanometers) allows them to interact with 
biological entities in a fundamentally different manner than non-nanostructured 
materials (Albanese et al. 2012). Some of those size-dependent properties 
derive from the surface to volume ratio being much higher than for non-
nanostructures materials. These properties can be exploited to design 
nanostructures that can be used to diagnose or treat different pathologies. 
Some examples would be the unique thermal, electrical, magnetic and optical 
properties that present different types of nanoparticles and that greatly differ 
from the properties of non-nanostructured materials with similar chemical 
composition (Chen et al. 2016). 
The design of nanoparticles is essential to allow their correct function for 
biomedical application. Amongst the most important parameters to consider are 
nanoparticle size, chemical composition and surface characteristics (Chen et al. 
2016). For example, nanoparticle size is critical for in vivo imaging as well as for 
therapeutic application of nanoparticles. As it will be explained later in this 
chapter, nanoparticles tend to accumulate in tumor tissue, due to an enhanced 
permeation and retention (EPR). In that context, if the particles are too big, they 
will not be able to reach the diseased tissue and, therefore, they will not achieve 
their function. On the other hand, if the nanoparticles are too small (less than 10 
nm), they will be excreted in the urine, potentially preventing accumulation in 
the desired target, which would lead to, again, the material not achieving its 
function. For in vitro diagnostics, the size of nanoparticles is also a fundamental 
parameter, since it often determines the optical properties of the nanoparticle 
suspension (for example, in plasmonic gold nanoparticles), and a modification 
in size will lead to changes in the measured response after exposure to a 
sample containing the analyte. 
This chapter is divided in three parts. In the first one, some of the most 
important types of nanoparticles proposed for biomedical application will be 
classified based on their chemical composition. Then, the rationale for their use 
in medicine will be explored in two different applications, each with their needs 
and particularities: diagnostics (in vitro diagnostics and in vivo imaging) and 
therapy (or the combination of diagnostic and therapeutic nanoparticles: 
theranostics) (Figure 1). 
 
Figure 1. Representation of the three applications of nanostructures in 
medicine that will be described in this chapter: In vitro diagnostics, in vivo 
imaging and therapy. 
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2. Types of nanoparticles for nanomedicine. 
A wide variety of nanoparticle types have been proposed for nanomedicine, 
some of the most important ones are going to be highlighted in this chapter. 
These types of nanoparticles will be classified based on their chemical 
composition in organic or inorganic nanoparticles (Figure 2). However, 
nowadays a very high percentage of the nanoparticles under evaluation are 
actually hybrid nanoparticles, joining organic and inorganic structures to yield 
multifunctional materials. These materials will be treated inside the section 
regarding the organic or inorganic core nanoparticle used to obtain the hybrid. 
 
Figure 2. Schematic representation of some of the most important types of 
nanoparticles used for nanomedicine, divided by their chemical composition. 
2.1 Organic nanoparticles 
2.1.1 Liposomes and lipid nanoparticles 
Liposomes are one of the most widely evaluated types of nanoparticles for 
biomedical application, and they have already reached clinical use (Bozzuto & 
Molinari 2015). Liposomes consist of amphiphilic lipids arranged in vesicles with 
an aqueous cavity surrounded by one or more lipid bilayers. 
Liposomes can be prepared by different methods, being the most common ones 
reverse phase evaporation or vesicle extrusion (Bozzuto & Molinari 2015). They 
can be produced with natural or synthetic lipids and their chemical composition, 
size, lipid bilayer structure and surface charge (amongst other parameters) will 
determine the formulation characteristics, from the stability to the drug release 
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behavior. For example, the stability of liposomes can be increased by the 
incorporation of cholesterol in their structure, which induces a denser packing of 
the hydrophobic chains inside the lipid bilayer. On the other hand, drug release 
from unilamellar liposomes is usually faster than from multilamellar ones, since 
the drug has to diffuse through more lipid bilayers in the second case. 
Liposomes can load hydrophilic molecules in the inner aqueous compartment 
(as is usually the case in unilamellar liposomes) or hydrophobic ones, in that 
case inserted in the lipid bilayer (mostly used in multilamellar liposomes). The 
combination of liposomes with other types of nanoparticles can yield 
multifunctional systems that allow simultaneous therapy and diagnosis 
(theranostic materials), for example, by conjugating the liposomes with 
nanoparticles with imaging capabilities, like quantum dots (optical imaging) or 
superparamagnetic iron oxide nanoparticles (magnetic resonance imaging). All 
of these characteristics, together with their high biocompatibility, easy 
preparation with tunable sizes and high loading capacity make them the most 
successful nanostructured drug delivery system to date (Bozzuto & Molinari 
2015). However, they present a rather low physicochemical stability compared 
to other nanoparticles.  To increase nanoparticle stability, solid lipid 
nanoparticles can be obtained by using high-melting lipids. These lipid 
nanoparticles can be stabilized in aqueous suspension by adding surfactants or 
other functionalities (Bozzuto & Molinari 2015). 
2.1.2 Micelles and solid polymeric nanoparticles 
Polymeric micelles are also amongst the most studied nanocarriers. They are 
colloidal nanoparticles with a size around 5-100 nm, constituted by an 
amphiphilic block copolymer that self-assembles in aqueous medium 
(Oerlemans et al. 2010).  At low concentrations, amphiphilic molecules are 
dissolved in the aqueous medium, but with increasing concentration, once the 
critical micellar concentration (CMC) is reached, the amphiphiles self-assemble, 
forming a hydrophobic core with a hydrophilic shell stabilizing the particles by 
hydrogen bonding with the surrounding water. The CMC of polymeric micelles is 
usually very low, which allows the presence of micelles at almost any dilution 
(Oerlemans et al. 2010). The polymer composition determines the micelle 
characteristics, like the drug molecules that can be loaded or the stability and 
biodistribution of the formulation. For example, the most common hydrophilic 
block is a chain of polyethyleneglycol (PEG), because it can stabilize the 
micelles and prevent the rapid uptake by the Reticuloendothelial system (RES) 
after injection. The polymer composition can also be modified to provide 
different functionalities to the material. A targeting moiety can also be included 
in the hydrophilic shell, as well as different components that provide imaging 
capabilities (like superparamagnetic iron oxide nanoparticles) to obtain 
theranostic nanodevices.  Micelles can efficiently carry high amounts of 
hydrophobic drugs within their core, preventing the use of toxic adjuvants that 
would be necessary to administer the free hydrophobic drug. However, they 
have poor stability and cannot carry high amounts of hydrophilic molecules.  
Other polymeric nanoparticles can also be prepared from natural or synthetic, 
biodegradable or non-biodegradable polymers (Kumari et al. 2010). Amongst 
them, biodegradable nanoparticles are preferred, due to a better safety profile. 
These particles have higher stability and the vast amount of polymers available 
make them a very versatile choice to develop particles for nanomedicine. Some 
of the most common methods to obtain polymeric nanoparticles are 
emulsification-diffusion, solvent emulsion-evaporation, nanoprecipitation, 
interfacial deposition and inotropic gelation (for example, in the case of 
polycations). They can load different types of drugs depending on the chemical 
nature of the chosen polymer; however, the loading efficiency is usually lower 
than with other types of nanocarriers. The most commonly biodegradable 
polymers used to develop nanoparticles for nanomedicine are: Poly-D,L-lactide-
co-glycolide (PLGA), Polylactic acid (PLA), Poly-ε-caprolactone (PCL), chitosan 
and gelatin (Kumari et al. 2010). Protein nanoparticles (like those made of 
albumin) have also attracted great attention, because of the high 
biocompatibility and biodegradability behavior, and their high chemical 
versatility due to the large amount of different free functional groups throughout 
the biopolymer structure. 
2.1.3 Dendritic nanoparticles 
Dendrimers are hyperbranched polymers that can be obtained with different 
functional groups. They can be prepared in a highly defined way (with a 
polydispersity index close to 1) (Khandare et al. 2012). Some of the most used 
dendritic molecules are polyamidoamine (PAMAM), poly(propylene imine) and 
polyglycerol. Branched polymers present several advantages for biomedical 
application, for example, they have shown a longer blood circulation half-life 
than linear polymers with similar molecular weight and chemistry (Khandare et 
al. 2012). The obtention of polycationic dendrimers allows gene therapy 
application (due to the interaction with negatively-charged nucleic acid 
molecules). An important disadvantage of these types of materials might be the 
significant cytotoxicity found for highly charged polycations.  
2.2 Inorganic nanoparticles: 
2.2.1 Metal-based nanoparticles 
A wide variety of metallic nanoparticles can be obtained for biomedical 
application. The synthesis of these nanoparticles is in general very tunable and 
allows the preparation of monodisperse nanoparticles that can be easily 
modified afterwards (Boisselier & Astruc 2009). Gold nanoparticles in 
particular have been extensively studied for diagnostics and therapy. Gold 
nanoparticles ranging from 3 to more than 120 nm present a phenomenon 
called surface plasmon resonance, which allows their use for photodiagnostics 
and photothermal therapy. Moreover, not only spherical nanoparticles can be 
synthesized, but gold nanorods with different aspect ratios (ratio of length 
between long and short axis of the nanoparticle) can be obtained, with profound 
impact in the properties of those colloidal nanoparticles. Silver nanoparticles 
with plasmonic behavior can also be obtained. One of the most promising 
applications of silver nanoparticles is in antibacterial nanodevices, due to the 
bactericidal effect of the ion Ag+ (Boisselier & Astruc 2009). 
Fluorescent semiconductor nanocrystals (Quantum dots, QDs) are inorganic 
fluorophores with very small diameter (2-10 nm) composed of a are single 
crystal of a semiconductor (like CdS, PbSe) or core/shell structures of two 
semiconductors (like CdSe/ZnS) (Azzazy & Mansour 2009; Michalet 2005). 
Compared to organic dyes, quantum dots have a broad-range excitation 
spectrum and a very narrow emission band, and their photostability is much 
higher. They have been studied very extensively for in vitro diagnostics and in 
vivo imaging.  Near-Infrared (NIR)-emitting QDs hold great promise for in vivo 
imaging, since NIR light is known to penetrate more in living tissue and shows 
much better signal-to-noise ratio (due to less autofluorescence in that range), 
however, most NIR-emitting QDs currently known are significantly less stable 
than visible-light emitting QDs. An important concern with QDs is regarding their 
potential toxicity in vivo after the metal ions they are composed of are released 
from the material. For this reason, heavy metal-free quantum dots are gathering 
great interest for their biomedical use (Yaghini et al. 2016). 
Nanoparticles for photon upconversion can also be prepared from rare earth 
ions (for example Er3+ or Yb3+) dispersed in a dielectric lattice (Azzazy & 
Mansour 2009). These kinds of particles can be excited by two or more low-
energy photons (usually in the NIR range) and emit one higher energy photon 
(generally in the ultraviolet or visible region). Therefore, they present many 
advantages for biomedical use, as they can be excited deep inside the 
organism (by highly-penetrating NIR light) and then emit UV or visible light to 
elicit the desired biological effect. They present very high photostability and low 
toxicity. Many formulations have been developed by joining upconversion 
nanoparticles with other particles or functionalities that can respond to the 
emission from these particles after NIR irradiation. 
Superparamagnetic nanoparticles (like maghemite, γ-Fe2O3, and magnetite, 
Fe3O4, nanoparticles) present very interesting properties for their use in 
biomedicine (Banerjee et al. 2010). When these types of nanoparticles have 
less than 50 nm in diameter, the whole nanoparticle acts as a single magnetic 
domain, showing superparamagnetic behavior. Without an applied magnetic 
field, the particles do no present macroscopic magnetization, what eliminates 
the possibility of agglomeration of the nanoparticles due to their magnetic 
behavior, which is of outmost importance if the nanoparticles are to be injected 
in a living organism. Superparamagnetic iron oxide nanoparticles have been 
extensively studied as in vivo imaging tools (Through magnetic resonance 
imaging, for example) and therapeutic agents, due to their capacity to induce a 
rise in the local temperature when exposed to an alternating magnetic field. 
These types of nanoparticles can also be induced to accumulate in the 
diseased area by the application of a magnetic field that can slow down 
nanoparticle flow at the desired site, easing extravasation. While these types of 
nanoparticles are well tolerated and generally considered to be non-toxic, some 
toxicity may be derived from the generation of Reactive Oxygen Species (ROS) 
from iron oxide nanoparticles via the Fenton reaction (Baeza 2014). 
2.2.2 Carbon-based nanoparticles 
Different carbon-based materials have been proposed for biomedical 
application. Fullerenes and carbon nanotubes are hollow structures that consist 
of one or several graphene-like sheets shaped as a sphere (fullerene) or a 
cylinder (carbon nanotube) (Ji et al. 2010). The structure of sp2-bonded carbon 
atoms confers graphene, carbon nanotubes and fullerenes unique electrical 
properties. Graphene oxide has also been proposed for drug delivery and gene 
transfection (Shen et al. 2012). Mesoporous carbon nanoparticles and 
luminescent carbon dots have also been proposed for biomedical application. In 
order to give stable suspensions in aqueous environment, these carbon-based 
materials have to be modified with hydrophilic moieties on their surface. They 
have a high physicochemical stability and their size and morphology can be 
finely tuned. The particular electrical properties of carbon nanotubes can be 
exploited in the design of biosensors. However, issues regarding their toxicity 
may hinder their translation to the clinical setting for in vivo application. The 
safety profile of carbon-based nanoparticles is a matter of discussion, as it 
appears that particle parameters such as size and surface properties can affect 
the toxicological characteristics of the material (Zhang et al. 2014). 
2.2.3 Silica nanoparticles 
Silicon oxide (silica) nanoparticles have been thoroughly studied as model 
nanoparticles for a wide variety of applications. Silica is not cytotoxic and its 
excellent physicochemical stability allows multiple functionalization strategies. 
Mesoporous Silica Nanomaterials have attracted a lot of interest in the context 
of drug delivery, since their very high surface area enables them to load high 
amounts of drugs within their pores (Mamaeva et al. 2013; Vallet-Regi et al. 
2001). The textural parameters of the nanoparticles, such as surface area and 
pore size can be finely tuned depending on the needed characteristics for a 
particular application. Surface functionalization to ensure nanoparticle 
suspension stability is needed to allow these nanoparticles to achieve their 
function in vivo. Mesoporous Silica Nanoparticles for therapeutic and diagnostic 
applications have been developed, in most cases by obtaining hybrid 
nanoparticles by modifying the inner or outer structure of the silica particles with 
other nanoparticles or molecules that provide the desired function to the 
material (Mamaeva et al. 2013; Li et al. 2012). Also, Mesoporous Silica is 
known to undergo dissolution under physiological conditions, giving rise to non-
toxic products that can be excreted from the organism. A potential drawback of 
these materials might be their high rigidity, which may obstruct their 
penetrability in solid tissues.  
3. Nanoparticles for diagnostics 
A promising approach in nanomedicine is the use of nanoparticles to develop 
diagnostic tools. Nanoparticles can be used for in vitro detection of 
pathologically relevant analytes. They can also be used as imaging agents for in 
vivo imaging. 
3.1 In vitro diagnostics 
The size of nanoparticles (typically bellow 100 nm) is in the same range as that 
of many biomolecules (enzymes, antibodies, other proteins). This fact allows an 
intimate interaction between both structures, which can be seized to develop in 
vitro setups that enable the detection of a wide variety of analytes. The high 
surface to volume ratio of nanoparticles allows the interaction of a large number 
of biomolecules with a single nanoparticle, potentially enabling detection of the 
analyte with very high sensitivity (Chen et al. 2016). Besides the potential 
implications of these strategies in the evolution and growth of analytical 
chemistry, the highly sensitive detection of pathologically relevant analytes in 
biological fluids could dramatically improve the diagnosis of several diseases, 
potentially improving the prognosis of many patients thanks to an early 
diagnosis (Azzazy & Mansour 2009). Amongst the plethora of nanoparticles that 
have been developed for in vitro diagnostics, we will only review a few of them 
in order to illustrate some of the most common strategies.  
Inorganic nanoparticles are of particular interest for in vitro diagnostics, 
especially gold nanoparticles, quantum dots and superparamagnetic 
nanoparticles (Azzazy & Mansour 2009). Different strategies developed for in 
vitro diagnostics can be divided by the parameter measured as well as by the 
types of nanoparticles that are used for that detection. 
3.1.1 Assays based on fluorescent nanoparticles 
A wide variety of methods can be used to develop fluorescent nanoparticles that 
act as sensors for different molecules (Chen et al. 2016). For example, an 
organic fluorophore can be introduced in the nanoparticles, either as part of the 
structure or loaded within them. An archetype of this type of systems are the so 
called "probes encapsulated by biologically localized embedding" or PEBBLEs. 
These systems have been adapted to be able to detect changes in pH, oxygen 
concentration and temperature, among others, by means of a change in 
fluorescence after exposure to the particular stimulus (Azzazy & Mansour 
2009). 
QDs have also been very thoroughly evaluated for this application, since they 
present much higher photostability and a much narrower emission band than 
organic dyes. Also, one of their main disadvantages for other biomedical 
applications, the potential toxicity due to heavy metals in their structure, is not 
relevant in this application, since the nanoparticles would never enter in contact 
with the organism of the patient. Sensors based on QDs have been developed 
to measure pH, temperature and different analytes (Azzazy & Mansour 2009). 
For example, a sensor to detect maltose was developed by grafting a maltose-
binding protein to the surface of QDs (Medintz et al. 2003). Then, a dark 
quencher conjugated with a cyclodextrin was used to occupy the maltose-
binding site of the protein, eliminating the fluorescence of the QDs by 
Fluorescence Resonance Energy Transfer (FRET). Then, after addition of the 
analyte, maltose displaced the dark quencher from the protein, allowing the 
recovery of nanoparticle fluorescence, enabling a straightforward measurement 
of maltose concentration. Similar concepts have been evaluated to determine 
the concentration of specific proteases and other molecules (Azzazy & Mansour 
2009). 
Upconversion nanoparticles are also promising for in vitro diagnostics because 
the excitation of the sample can be performed with NIR light, thus avoiding 
many potential interferences from molecules in the biological fluids that might 
be found when exciting the sample in the ultraviolet of visible range (where 
background signal is commonly found). Then, the emission in the visible part of 
the spectrum could be easily measured to determine the result of the test. Also, 
the excitation and emission spectra of upconversion nanoparticles are relatively 
independent of their environment, making them a good choice for detection of 
analytes in biological fluids that are often very complex. Upconversion 
nanoparticles have been used to develop detection methods for temperature, 
oxygen, nucelic acids, antigens and many other biomolecules (Azzazy & 
Mansour 2009).  
3.1.2 Assays based on plasmonic nanoparticles 
Plasmonic nanoparticles have been very extensively evaluated as the main 
component to develop in vitro diagnostic systems (mainly based on gold 
nanoparticles)(Chen et al. 2016). Localized Surface Plasmon Resonance 
(LSPR) is a phenomenon due to collective electron charge oscillations in the 
surface of some metallic (for example, gold) nanoparticles when they are 
excited by light. Since it is a surface phenomenon, any change in the surface of 
the nanoparticle (or its size, since it is a highly size-dependent phenomenon) 
will induce a change in the LSPR and, therefore, in the optical properties of the 
nanoparticle suspension, which can be then detected by a colorimetric method. 
The surface of the plasmonic nanoparticles can be modified to include a 
recognition molecule for the analyte of interest. After the interaction with the 
desired molecule, a modification on the surface due to the interaction with the 
recognition ligand will lead to a change in the color of the sample, which can be 
measured and analyzed to give a concentration of the analyte present in the 
medium. An excellent example is the home pregnancy test, which is a 
colorimetric assay for the detection of human gonadotropic hormone, and is 
based on gold nanoparticles (Azzazy & Mansour 2009). Gold nanosensors have 
also been developed to determine biomolecules due to nanoparticle 
aggregation when the analyte is present in the sample. The change in 
nanoparticle size and shape due to aggregation induces a change in the LSPR 
peak of a magnitude such that it is usually detectable by the naked eye. For 
example, systems for detecting DNA in the medium by decorating gold 
nanoparticles with complementary single strand DNA, inducing aggregation and 
a sharp change in the LSPR peak (Azzazy & Mansour 2009; Chen et al. 2016). 
The interaction of plasmonic nanoparticles with fluorophores can also be utilized 
to develop different types of nanosensors. When a florescent molecule is in 
close proximity to the surface of a plasmonic nanoparticle, there is a dipole-
induced quenching of the fluorophore. After being removed from the surface, 
the molecule will recover its fluorescence, which can be detected in the sample. 
A system based on this effect was developed to detect proteins in the sample, 
due to the specific displacement of a fluorescent polymer from the surface of 
gold nanoparticles caused by the analyte (You et al. 2007; Chen et al. 2016). 
Another type of sensors for in vitro diagnostics are those based on Surface 
Enhanced Raman Scattering (SERS), which can provide very high sensitivity 
and also giving information about the conformation of the analyte. For this 
reason, they are under extensive evaluation for immunoassays, amongst other 
applications (Chen et al. 2016).  
3.1.3 Assays based on superparamagnetic nanoparticles. 
A wide variety of superparamagnetic nanoparticles (especially iron oxide 
nanoparticles) have been developed for in vitro detection (Azzazy & Mansour 
2009). Upon exposure to an external magnetic field, superparamagnetic 
nanoparticles can be employed to capture different analytes that are bound to 
them (by interactions with recognition ligands decorating their surface), 
separating them from the sample medium. An example is an immunoassay 
detection method for C-reactive protein (CRP) based on this kind of 
nanoparticles (Kriz et al. 2006). A monoclonal antibody for CRP was grafted to 
the nanoparticle surface. A policlonal anti-CRP antibody was also conjugated to 
silica microparticles (to ease sedimentation). The increase in magnetic 
permeability of the sediment correlated with the amount of CRP in the sample 
(Azzazy & Mansour 2009). 
Superparamagnetic nanoparticles can also be used to separate pathogenic 
cells from healthy ones by decorating the nanoparticles with antibodies for 
specific markers of the pathogenic cells, which can then be separated from the 
rest of the sample by applying an external magnetic field or with the use of a 
magnetic needle (Azzazy & Mansour 2009; Bryant et al. 2007). 
3.1.4 Assays based on electric properties of nanostructures 
The particular electric properties of different nanoparticles (like carbon 
nanotubes) can also be exploited to develop in vitro nanosensors. The high 
surface area of single wall carbon nanotubes (SWNTs), up to 1600 m2/g allows 
grafting a vast amount of antibodies on their surface. The very efficient electric 
conductivity of SWNTs along their longitudinal axis (often referred to as ballistic 
electron conduction) enables the development of nanosensors with the desired 
performance. Such methods have allowed, for example, the development of a 
Prostate Specific Antigen (PSA) detection kit with better performance than 
commercial immunodetection assays, with a detection limit of 4 pg/mL (Ji et al. 
2010; Rusling et al. 2009). 
While all of the different strategies that have been briefly collected here are very 
exciting and promising for their application in clinical diagnostics, several 
problems are still to be addressed before the majority of them will reach the 
clinical setting. One of the most important ones is getting the nanoparticle-
based diagnostic assays to work properly in real complex biological fluids like 
those that are found in the clinical setting.  
3.2 In vivo imaging 
Another promising field for nanotechnology application in medicine, and still in 
the diagnostic context, is the use of nanoparticles as imaging agents in vivo. 
Due to several characteristics of diseased tissues, like tumors, nanoparticles 
can be preferentially located in those pathological locations. If the nanoparticle 
is designed in order to be detected generating some kind of image, then the 
clinician can take advantage of that selective accumulation of nanoparticles to 
provide a diagnosis or a prognosis of the pathological situation of a particular 
patient, or can be used to assess the evolution of the pathology throughout the 
treatment or the success of a surgical intervention. 
There are several means by which nanoparticles can be used to generate a 
diagnostic image in vivo, depending on the physical phenomenon in which 
those nanoparticles will be involved.  They can be divided in optical imaging, 
magnetic resonance imaging (MRI), radioisotope imaging and X-Ray computed 
tomography (CT) imaging. In the last years, the preparation of nanoparticles 
that enable the use of different imaging modalities simultaneously has been 
extensively evaluated. This multimodality can allow a single nanoparticle 
formulation to combine the advantages of the different techniques. Again, 
Inorganic nanoparticles will be of outmost importance in this context. 
3.2.1 Optical imaging 
Optical imaging methods are based on the difference in the optical properties of 
the contrast nanoparticle and the background signal from the surrounding 
tissue. Most of the current optical imaging nanodevices are based on 
fluorescent nanoparticles. Fluorescent nanoparticles (like QDs of dye-doped 
silica nanoparticles) present several advantages over traditional organic dyes, 
such as improved photostability (with greatly diminished photobleaching effect) 
and the capability to accumulate in the desired tissues by targeting strategies. 
The development of highly efficient NIR-emitting nanoparticles is a rising 
strategy in this context. QDs are specially promising due to their narrow 
emission spectrum in a finely tunable region (and heavy-metal free QDs would 
be highly desirable due to toxicity issues related to nanoparticles containing 
heavy-metal).  
Photoacoustic imaging is another strategy for optical bioimaging. It is based on 
the generation of an acoustic wave as a consequence of heat generated by light 
absorption by the contrast nanoparticles (Chen et al. 2016). It presents several 
advantages, since it combines the higher contrast of optical imaging with the 
higher penetration and spatial resolution of ultrasound imaging. One example of 
this strategy is the development of indocyanine green-loaded nanoparticles to 
provide photoaccoustic imaging in vivo (Witte et al. 2008). 
Upconversion imaging can be performed with upconversion nanoparticles, 
which show a significantly better safety profile than QDs. The excitation of these 
nanoparticles is generally in the NIR region, allowing the excitation of 
nanoparticles located deep inside the body. Besides, the imaging background 
can be diminished by using short-pass filters, since the emitted light is 
significantly shifted from the excitation source (Chen et al. 2016). Upconversion 
nanoparticles in which both the excitation and the emission wavelengths are in 
the Infrared region seem very promising for this application, since they allow the 
imaging of deep tissues and organs with a low background noise. An example 
of this kind of particles was developed with NaYF4 nanocrystals doped with Yb
3+ 
and Tm3+, showing an excitation wavelength of 975 nm and an emission one of 
802 nm (Nyk et al. 2008). 
3.2.2 Magnetic Resonance Imaging  
There are two modalities of MRI: T1 (relying on spin-lattice relaxation of protons 
in the organ/tissue) and T2 (dependent on spin-spin relaxation of protons in the 
organ/tissue). It creates images with good spatial resolution, but contrast agents 
are often needed to improve the sensitivity of the technique. These contrast 
agents are magnetically active species that can be divided in T1 or T2 agents 
depending on which of the modalities provides a better contrast with that 
particular contrast agent.  
The most common T1 contrast agents are species containing Gd (III) as the 
magnetic agent, chelated with either diethylamine pentaacetic acid (DTPA) or 
tetraazacyclododecane tetraacetic acid (DOTA)(Chen et al. 2016). These are 
the most widely used MRI contrast agents in the clinical setting, even though 
there is some concern about the toxicity of Gd (III) ions that can be released. 
Modifying the surface of nanocarriers with DTPA or DOTA in order to chelate 
Gd (III) is a very common and successful way to provide MRI capabilities to 
virtually any type of nanodevice that could be used simultaneously with 
therapeutic purpose. This kind of strategies allow for real-time monitoring of the 
therapy. Gd (III) ions can also be incorporated into an inorganic matrix of 
different types of nanoparticles (like upconversion nanoparticles) to provide MRI 
contrast ability. The use of nanoparticles capable of providing different imaging 
capabilities is promising, since they would allow taking advantage of the 
benefits of the different imaging modalities with a single formulation (Chen et al. 
2016). 
Superparamagnetic iron oxide (Fe3O4) nanoparticles can be used as negative 
T2 contrast agents (since they reduce the spin-spin relaxation of the proton and 
therefore, give a dark contrast). They have been used in clinical MRI and their 
lack of toxicity is one of their biggest advantages. However, the contrast that 
these types of particles provide is rather low, and has to be improved in order to 
be more extensively used (Chen et al. 2016). 
Another option would be using nanoparticles to produce magnetic resonance 
imaging using spin transitions of the nucleus of other species, like 19F. This 
isotope can be introduced in the structure of different nanoparticles in a fairly 
easy manner, allowing MRI with increased sensitivity and very low background 
noise, due to the lack of 19F in the organism. This promising strategy would only 
need minor modification in existing MRI devices to allow their use for 19F 
detection (Chen et al. 2016). 
3.2.3 Radioisotope imaging 
The incorporation of radioactive isotopes in different types of nanoparticles 
allows their use for in vivo imaging. The radioactive isotopes to be used are 
chosen to emit low energy species, so that there will not be any radiotoxicity 
derived from their use for bioimaging. The most common modalities of 
radioisotope imaging are positron emission tomography (PET) and single 
photon emission computed tomography (SPECT)  
In PET imaging, a radioisotope (like 124I or 64Cu) emits γ rays that after 
detection, are used to generate a three dimensional image. Nanoparticles allow 
a large number of radioisotope labeling, providing a great sensitivity and 
reducing the amount of contrast agent needed to perform the imaging. The 
most common ways to obtain nanoparticles for PET imaging are the use of 
chelators in the surface of the nanoparticles and radiolabeling by ion exchange 
within the nanoparticle matrix. SPECT imaging is based on a similar rationale, 
and suitable radioisotopes (like 125I) can also be included in a nanoparticle 
structure to evaluate nanoparticle distribution with whole-body in vivo SPECT 
imaging (Chen et al. 2016). 
3.2.4 X-ray Computed Tomography 
CT imaging is based on using several X-Ray scans to produce a tomographic 
image after being processed by a computer program. CT contrast is very high 
for hard tissues, but it is not sufficient when the objective is to image soft 
tissues, where a contrast agent is needed. Atoms with large atomic number 
provide high contrast in X-ray images, and are therefore used for CT imaging. 
For this reason, gold nanoparticles with different shapes have been extensively 
studied for CT imaging. Some of the main reasons are, besides the high 
contrast in X-ray, their easy synthetic procedures, biocompatibility and the 
capacity to finely tune their optical properties in order to combine CT imaging 
with other optical modalities. Other inorganic nanoparticles, like upconversion 
nanoparticles containing Yb have also been studied for this application (and 
also in combination with optical imaging modalities) (Chen et al. 2016; Liu et al. 
2012). 
4. Nanoparticles for therapy 
Nanoparticles can be designed for therapeutic application based on two 
different (but compatible) approaches: either the nanoparticle itself is the 
therapeutic agent that will exert the desired function (material-based therapy) or 
the nanoparticle is used as a carrier for a therapeutic molecule (constituting a 
nano-Drug Delivery System, nano-DDS). Nano-DDS can overcome many of the 
problems related to traditional drugs for the treatment of several diseases. They 
are particularly useful when dealing with toxic drugs of hydrophobic ones that 
are difficult to administer in a stable formulation. Therefore, nanomedicine can 
improve the bioavailability, and increase the target specificity while decreasing 
the systemic toxicity of a wide variety of drugs. The inclusion of drugs inside a 
nanocarrier can also protect the drug from degradation that might take place 
when exposed to the physiological environment (such as enzymatic 
degradation) (Chen et al. 2016). This can potentially allow the use of drugs that 
would otherwise be unable to reach the clinic, either due to poor solubility, 
systemic toxicity of lack of chemical stability. 
Multifunctional nanosystems can be obtained by adding therapeutic capabilities 
to the in vivo diagnostic nanoparticles already discussed, developing 
theranostic nanodevices. Nanoparticles can be used for a wide variety of 
pathological conditions, including infection, osteoporosis, gene therapy, cancer 
treatment and others (Chen et al. 2016). However, most of the research has 
been focused on the use of nanoparticles for cancer treatment. 
4.1 Cancer nanomedicine 
The most important reason why the vast majority of nanomedicine research has 
been focused on cancer is what has been called the Enhanced Permeation and 
Retention (EPR) effect (Figure 3). By that name, Maeda defined in the 1980s 
the preferential accumulation in tumor tissues of macromolecules and 
nanosized structures (Matsumura & Maeda 1986). This effect is possible due to 
the fast and chaotic growth of most solid tumors. During that indiscriminate 
growth, the tumor cells are capable of inducing the formation of blood vessels 
(in a process called angiogenesis) in order to receive enough nutrients and 
remove waste products from their metabolism. However, and in contrast to the 
formation of healthy blood vessels, this angiogenesis is fast and disorganized, 
leading to imperfect blood vessels, leaving pores in the walls of capillaries that 
are bigger than those in healthy tissues and organs. The presence of those 
pores or fenestrations allows the extravasation of large macromolecules and 
nanoparticles to the diseased site, what would not be possible in a healthy 
tissue (enhanced permeation). Besides that, solid tumors are generally very 
compact structures with a high interstitial pressure. Under those conditions, the 
lymphatic vessels present in the tissue will be blocked, preventing the drainage 
of extravasated particles (enhanced retention). The discovery of this 
phenomenon in the 1980s lead to the proposal of using nanoparticles to treat 
tumors, since the enhanced accumulation would allow the delivery of higher 
doses of antitumor drugs in the tumors, potentially reducing the dose of the drug 
and, therefore, reducing side effects without compromising the efficacy of the 
treatment. The EPR effect became then the main justification for the 
development of nanomedicine, and would provide what would be known in the 
field as a “passive targeting”. 
 Figure 3. Schematic representation of the enhanced permeation and retention 
(EPR) effect. 
Nanoparticle accumulation in the tumor area by the EPR effect relies on the 
circulation time of the nanoparticles in the bloodstream. After intravenous 
injection of the nanoparticles, a series of steps must take place to allow the 
EPR effect to take place. First, the nanoparticles have to be stable in 
suspension while circulating in the blood. Otherwise, nanoparticle aggregation 
will lead to the obstruction of blood vessels, potentially compromising the 
patient´s life. Then, the nanoparticles have to remain in the bloodstream long 
enough to extravasate to the tumor in a sufficient amount to elicit the 
therapeutic effect. One key aspect to consider regarding nanoparticle circulation 
time is the opsonization of the nanoparticles (Wicki et al. 2015). Opsonization is 
a process by which a pathogen or foreign body is surrounded by a type of 
proteins called opsonins. Opsonins act as a label for phagocitic cells to ingest 
the labeled structure in order to destroy it. When nanoparticles without any 
surface modification are put in contact with the blood, they are covered by a 
mixture of different proteins (forming what is called the protein corona). The 
formation of this protein corona can accelerate very dramatically the clearance 
of the nanoparticles from systemic circulation due to the presence of opsonins 
in its composition. One of the most employed strategies to slow down the 
formation of the protein corona consists on modifying their surface with highly 
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hydrophilic moieties that will hinder protein adsorption on the nanoparticle 
surface. The most common molecule to achieve this is polyethyleneglicol 
(PEG), and the process of coating a nanoparticle with PEG has been called 
PEGylation. 
PEGylation has been shown to significantly increase circulation time of 
nanoparticles and, therefore, their accumulation in tumors (Wicki et al. 2015). 
However, the protein corona will eventually form (although more slowly), and 
the nanoparticles that have not yet reached the diseased site will be removed 
from the circulation by the organs of the reticuloendothelial system (RES, 
mainly liver and spleen). It has been recently estimated that the amount of 
nanoparticles that arrive to the tumor tissue is in average less than 1% of the 
injected dose (Wilhelm et al. 2016). Even though that number seems low, it is 
greatly superior to the percentage of free drug that would reach the tumor site 
without the nanocarrier (Lammers et al. 2016). Moreover, several strategies can 
be applied to further improve nanoparticle accumulation in tumors, like injecting 
angiotensin II (a vasoconstrictor) to increase the systemic blood pressure and 
facilitate nanoparticle leakage to tumors (Maeda et al. 2013), normalizing tumor 
vasculature to diminish interstitial pressure within the tumor (Chauhan et al. 
2012)  or destabilizing the blood vessels in the tumor by hyperthermia or 
ultrasound to increase their permeability (O’Neill et al. 2009).  
4.1.1 Active targeting of nanoparticles 
In order to improve the efficacy of nanoparticles for therapy, a second strategy 
of nanoparticle targeting was then developed, the one known as “active 
targeting”. Active targeting is based on decorating the nanoparticle surface with 
molecules that would induce selective internalization in tumor cells, and 
decreasing the amount of particles that would reach healthy cells. When the 
release of the cytotoxic agent takes place inside the tumor cell, the high local 
concentration of the drug would increase its efficacy, lowering even more the 
required dose of the highly toxic antitumor drug. The most studied types of 
molecules used for active targeting are either nutrients (for which the tumor 
cells overexpress receptors, due to their high demand to allow their rapid 
growth) or antibodies (for specific antigens present in the tumor cell membrane). 
These targeting molecules can be small molecules (like folic acid (Stella et al. 
2000) or biotin (Yang et al. 2009)) or macromolecules (like the protein 
transferrin) (Greish et al. 2014). Another step of nanoparticle targeting can take 
place after cellular uptake of the nanodevice. In this case, the surface of the 
nanoparticles is also decorated with moieties that can drive nanoparticle 
accumulation in a particular subcellular structure or organelle. For example, 
nanoparticles presenting triphenyl phosphonium moieties on their surface are 
known to target the mitochondria, and are often used to carry drugs that act at 
the mitochondria, increasing the therapeutic efficacy of the nanodevice.  
It is worth noting that, since active targeting strategies involve the interaction of 
nanoparticle with a receptor in the target cell membrane, this strategy relies on 
passive accumulation first, which would bring the particles close enough to the 
cells so that active targeting can take place. Once the nanoparticle has reached 
the tumor environment and has interacted with the tumor cell receptors, another 
consideration must be taken. If the interaction with the cell receptor is very 
efficient in inducing nanoparticle uptake, a paradoxical effect can appear. The 
first line of cells in the tumor will internalize all of the nanoparticles, preventing 
their penetration to deeper areas. This might hinder the therapeutic efficacy of 
the nanoparticles, since most of the tumor will not be exposed to them. In order 
to try to solve this issue, hierarchical targeting strategies are being developed 
(Wang et al. 2016). In these strategies, the targeting moiety is hidden until the 
nanoparticles are already distributed in the tumor. Then, the presence of an 
internal or external stimulus will induce the exposure of the targeting moiety, 
allowing particle uptake by the tumor cells. These kinds of strategies would also 
be useful to increase the circulation time of those targeted nanoparticles, since 
the presence of targeting moieties on the surface of PEGylated nanoparticles 
has been shown to facilitate their removal from the bloodstream by the RES 
(Wang et al. 2016). If the targeting ligand is hidden until after the nanoparticles 
have accumulated in the tumor, the nanoparticles will be able to remain in the 
circulation for longer periods of time. After extravasation to the tumor tissue, 
PEGylated nanoparticles are poorly internalized in tumor cells (due to what has 
been called the "PEGylation dilemma") (Hatakeyama et al. 2013). However, 
with these hierarchical targeting strategies, the exposure of the targeting 
molecule will allow their successful internalization in tumor cells, increasing their 
therapeutic efficacy (Wang et al. 2016). 
Besides this problem, other considerations must be taken into account. First, 
nanoparticle diffusion in tumor tissues is hindered by the high interstitial 
pressure. Therefore, the size of the nanoparticles will be a key factor in 
determining whether the particles can reach deeper areas of the diseased 
tissue. To attack this problem, size-changing materials are being developed to 
allow for a deeper penetration once the nanoparticles have reached the tumor 
(Wang et al. 2016). Besides, strategies directed to reducing interstitial pressure 
are also interesting approaches with potential to obtain very positive results (like 
using collagenase prior to nanoparticle injections) (Goodman et al. 2007).  
All the strategies we have discussed so far depend on the EPR effect to induce 
selective accumulation of the nanoparticles in the tumor microenvironment. 
However, it is well established that the EPR effect presents a very high 
variability, even amongst tumors of the same type, and it changes greatly when 
discussing different tumor types (Greish et al. 2014). Two possibilities arise 
from this perspective: either developing methods that would allow for a selection 
of patients that are most likely to respond to nanoparticle-mediated therapy (by 
determining whether their particular tumor presents a strong EPR effect or not), 
or developing new strategies to induce nanoparticle accumulation in tumors that 
do not rely on the EPR effect (Greish et al. 2014; Hu et al. 2010).  
4.1.2 Material-based therapeutic approaches  
Several approaches have been studied to induce therapeutic effects by using 
nanoparticles without relying on drug release, because the nanomaterial itself is 
responsible for the desired response. These effects are often used in 
combination with drug release from the same nanoparticles, looking for a 
synergistic effect between them. Some of the most important ones will be briefly 
mentioned here. 
Photodynamic therapy (PDT): PDT is a type of therapy involving two 
components: light and a molecule called photosensitizer. None of them are toxic 
individually, but they are capable of inducing cell death when they are 
combined. Photosensitizers (generally porphyrin molecules) can be excited by 
light (at different wavelengths depending on the particular photosensitizer) into 
a triplet state. This excited photosensitizer in its triplet state can transfer its 
energy to oxygen in the medium, producing highly reactive singlet oxygen 
(Chen et al. 2016). The short half-live of singlet oxygen implies that only the 
cells very close to the photosensitizer will be affected by the generation of those 
reactive oxygen species (ROS). Since photosensitizers share many 
shortcomings with other drugs regarding their poor solubility and difficulty to get 
high concentrations in the tumor tissue, the use of nanoparticles to transport 
them to the desired area of the body has emerged as a very powerful tool to 
increase the efficacy of PDT (Chen et al. 2016). As PDT will happen 
independently of whether the photosensitizer is free in solution or inside a 
nanoparticle, the sensitizer can be included in the formulation without having to 
be released to induce the desired effects. 
Photothermal Therapy (PTT): In PTT, the nanoparticle itself is responsible for 
the biological effects of the therapy. PTT is mainly based on the plasmonic 
absorption of metallic nanoparticles. Metallic nanostructures can be designed to 
absorb Near-Infrared (NIR) or Infrared (IR) light, generating heat as a 
consequence. If the nanoparticles are embedded inside a tumor mass, the 
increase in the temperature will eventually cause cell death by necrosis (cancer 
cells are more vulnerable to hyperthermia than healthy cells, in a temperature 
range 40-43ºC)(Chen et al. 2016; Hildebrandt 2002). Gold nanorods are 
amongst the most studied nanoparticles for PTT, since they can generate heat 
very efficiently when exposed to NIR light, while also having an easy and finely 
tunable synthesis. Another type of nanoparticles that is under extensive 
evaluation for PTT is graphene oxide, which has been shown to generate heat 
when exposed to 800 nm lasers. Also, incorporating NIR dyes or porphyrins in 
the structures of different nanoparticles not only allows their use for imaging, but 
also the generation of PTT (obtaining theranostic nanodevices) (Chen et al. 
2016). 
Magnetic hyperthermia: Besides the possibility to increase accummulation of 
superparamagnetic nanoparticles in tumors by the application of an external 
magnetic field (magnetic targeting), these nanoparticles can also generate heat 
when exposed to an alternating magnetic field (Chen et al. 2016). In the same 
way as for PTT, the local heating caused by magnetic hyperthermia can cause 
the death of cancer cells without the need for any drug molecules to be 
released from the material. The possibility of obtaining theranostic nanodevices 
for magnetic hyperthermia is also exciting, since superparamagnetic iron oxide 
nanoparticles that can be employed to induce it can also be used to provide 
MRI capabilities. 
4.1.3 Nano-Drug Delivery Systems 
Most of the work that has been developed about the therapeutic application of 
nanoparticles involves using them as DDS, so that they can improve the 
pharmacokinetic parameters of different active molecules, getting them to the 
site of action. Once the nanoparticles are located in the tumor area, 
nanoparticles carrying cytotoxic drugs will have to release them so that they can 
perform their action. The nanoparticles acting as nano-DDS can be designed to 
present a controlled release of the drugs they contain. Nanoparticles can be 
prepared to provide prolonged release of the drug, for example by introducing 
the active molecule in a biodegradable matrix (PLGA nanoparticles are a typical 
example of this strategy) (Chen et al. 2016). As the nanoparticle degrades, the 
drug is released to the medium, and carries out its function. However, since 
anticancer drugs are highly toxic, it would be very interesting to develop a 
nanocarrier that can release such drug only in the diseased site, without any 
drug loss during transport. In that context, as plethora of stimuli-responsive 
materials have been evaluated (most of them in vitro, although many in vivo 
evaluations have also been performed). In these materials, drug release is 
hindered by some component in the formulation that can respond to differences 
in its environment, inducing a change in the formulation that will lead to drug 
release. The different stimuli that can be employed to this end can be divided in 
internal and external stimuli (Figure 4). 
 Figure 4. Concept of stimuli-responsive drug release. Different stimuli reported 
in the literature divided in internal or external stimuli. 
 
Internal stimuli are differences in tumor tissues or tumor cells that are not 
present in the healthy counterparts (or are much less intense). Therefore, once 
the nanoparticle is in the tumor, the presence of such stimulus will induce some 
change that will provoke drug release. Typical examples of internal stimuli in 
cancer therapy are pH (tumors possess a lower pH than healthy tissues, and 
the pH in some intracellular compartments, like lysosomes, is also much lower 
than in the extracellular medium) (Liu et al. 2010), redox potential (which also 
presents significant changes in the intracellular compartment compared to 
extracellular media) (Z.-Y. Li et al. 2015), and the presence of different proteins 
or signaling molecules (like Matrix MetaloProteases, MMPs) (Singh et al. 2011). 
For example, pH-responsive mesoporous silica nanoparticles can be obtained 
by grafting gold nanoparticles acting as gatekeeper through a pH-labile acetal 
group (Liu et al. 2010). Once the nanoparticles are exposed to an acidic pH, the 
acetal linker is cleaved and the cargo inside the nanoparticle pores can be 
released. Another example are redox-responsive polymeric nanoparticles that 
can be obtained by the introduction of disulfide bonds inside the polymer 
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structure (Song et al. 2011). Once in the reducing intracellular environment, the 
disulfide bonds are broken and the nanoparticle releases its cargo.  An 
advantage of internal stimuli is that once the nanoparticle is administered, no 
further action is needed from the clinician. This would in theory ease the 
translation of these strategies. However, a general piece of criticism towards 
these stimuli is that most of the differential characteristics between healthy and 
tumor tissues are not as exacerbated in reality as it is supposed in most 
research articles dealing with them, what would hamper the correct behavior of 
the material in real clinical situations. 
On the other hand, external stimuli have also been extensively evaluated. 
External stimuli are not present in the organism and they are not a 
consequence of the pathology. They are exogenous agents that the clinician 
might apply to the diseased site after the administration of the nanocarrier and 
would then interact with the formulation, inducing drug release. Examples of 
external stimuli that have been evaluated are light (Martínez-Carmona et al. 
2015), magnetic field (Guisasola et al. 2015) or ultrasound (Grüll & Langereis 
2012; Schroeder et al. 2009; Li et al. 2016; Paris et al. 2015). For example, 
light-responsive liposomes can be obtained by taking advantage of the same 
effect as the one used for photodynamic therapy. A photosensitizer can be 
included in the formulation, as well as an unsaturated lipid. Once the 
formulation is exposed to light, ROS are generated, inducing the peroxidation of 
the unsaturated lipid component of the lipid bilayer (Carter et al. 2014). The lipid 
bilayer permeability is therefore modified, inducing drug release. As an example 
of magnetic-responsive drug release, superparamagnetic nanoparticles 
embedded in a mesoporous silica matrix can be employed to induce an 
increase in the local temperature when exposed to an alternating magnetic field, 
what can then induce a conformational change in a temperature-responsive 
polymeric gate, allowing cargo release from the material (Guisasola et al. 2015). 
An advantage of these kinds of stimuli is that, since they are not present in the 
organism, designing formulations that are sensitive to them will provide a high 
selectivity in the material response. On the other hand, there are several 
concerns about their use, like the poor penetration of the stimulus in the 
organism (for example, with light), difficulty to focus the stimulus in the tumor or 
toxicity associated to the stimulus alone.  
4.2 Nanomedicine for other applications 
4.2.1 Infection: Nanoparticles can be used to deliver different antimicrobial 
drugs to treat different infectious diseases, by developing the so-called 
"nanoantibiotics" (Huh & Kwon 2011). Nanoantibiotics can be developed by 
using nanoparticles with inherent antimicrobial activities (like Ag nanoparticles, 
fullerenes or chitosan nanoparticles) or by acting as drug delivery vehicles that 
can release antimicrobial drugs (Huh & Kwon 2011). Antibiotic-loaded 
mesoporous Silica Nanoparticles have been proposed for intracellular 
pathogens like Francisella tularensis (Z. Li et al. 2015). The main rationale for 
this work was the fact that F. tularensis is found in macrophages of the infected 
host. Macrophages are professional phagocytes that tend to engulf large 
amounts of nanoparticles after they are injected in the bloodstream. Once 
nanoparticles have undergone uptake by them, the antibiotic moxifloxacin was 
released, killing the bacteria inside the macrophages and showing promising in 
vivo results for the treatment of Lethal Pneumonic Tularemia (Z. Li et al. 2015). 
Antimicrobial nanomedicine has gained great attention due to antibiotic 
resistance. Nanoantibiotics can be used to deal with this problem either by 
taking advantage of different mechanisms of action (less likely to induce 
resistance, like using silver or other metal nanoparticles), by better targeting the 
diseased site or by employing combinations of different drugs in a single 
formulation (combination therapy). 
4.2.2 Osteoporosis: Osteoporosis is nowadays one of the main reasons of 
morbidity in the aging population (Luhmann et al. 2012). Nanoparticles have 
been proposed for the treatment of osteoporosis in order to try to improve the 
efficacy of anabolic (increasing bone production) and anti-resorptive 
(decreasing bone elimination) therapy (Luhmann et al. 2012). This could 
happen mainly by increasing the local concentration of the drugs of interest in 
the diseased site. For that reason, different strategies have been developed to 
improve bone targeting of nanomedicines, mainly by decorating the 
nanoparticle surface with different bisphosphonates (that present a strong 
interaction with calcium present in the inorganic phase of bone, hydroxyapatite) 
or with the collagen binding domain of different proteins (targeting therefore 
collagen, the main organic component of bone) (Luhmann et al. 2012). Once 
located in the diseased bone, the nanoparticles can be used to release different 
therapeutic agents, like Parathyroid Hormone (PTH) or Bone Morphogenetic 
Proteins (BMPs), which are growth factors that have been extensively studied 
for bone regenerative therapy (Luhmann et al. 2012). 
4.2.3 Gene Therapy: A great number of diseases are caused by a malfunction 
of one or several genes, and gene therapy implies a modification in the 
structure or expression of such genes to treat the pathologies that arise from 
that malfunction. The main barriers that gene vectors encounter to allow 
effective gene therapy are: prevention of degradation of the nucleic acid (DNA 
or RNA), efficient uptake by the target cells, release of the nucleic acid in the 
cytoplasm and outside of the endolysosomal system, entering the nucleus and 
producing sufficient gene expression (Chen et al. 2016). The use of a targeted 
nanocarrier that can protect the nucleic acid during transport and can release it 
in the proper location can therefore overcome most of those concerns. 
Especially appealing is the strategy of delivering small interference RNA 
(siRNA) to modify the expression of different genes of interest. The most 
common way of introducing nucleic acids in a nanoformulation is through the 
electrostatic interaction between the negatively charged nucleic acid (DNA or 
RNA) and a positively charged nanostructure, generally by using polycationic 
polymers. Among all the available polycations, the ones that are most widely 
used are polyethyleneimine (PEI, either linear or branched), PAMAM and 
chitosan (Chen et al. 2016). Besides polymeric nanoparticles composed of 
these kinds of polycations, liposomes with positively charged lipids are also very 
widely used for this application. The use of nanoparticles with high positive 
charges presents another advantage: lysosomal escape capacity. Nanoparticles 
with protonable groups under acidic conditions are capable of inducing 
lysosomal escape via the Proton Sponge Effect. Once the nanoparticles are 
inside the lysosomes after endocytosis, at the lysosomal low pH, the protonable 
groups acquire a high positive charge, which would tend to be neutralized by 
the entrance of chloride anions. These osmotically active ions enter the 
lysosomes accompanied by water, making the lysosome swell until it bursts, 
releasing the nanoparticles in the cytoplasm (Sahay et al. 2010). The 
nanoparticles can also be modified by endosomolytic agents to induce 
lysosomal escape of the nucleic acid-carrying nanoparticles (Chen et al. 2016).   
5. Conclusion 
Nanomedicine is a multidisciplinary field aimed to develop diagnostic and 
therapeutic tools based on nanoparticles with different chemical compositions. 
The selection of a particular nanoparticle type and their further modifications are 
selected based on the particular application of interest.  
The great versatility of nanotechnology enables the design and preparation of 
highly sensitive and specific diagnostic assays that could allow early detection 
of different pathologies, hopefully improving the prognosis of the patients. 
Nanoparticles can also be used in vivo for the diagnosis and treatment of 
several diseases (sometimes at the same time, by developing theranostic 
nanoparticles). With the help of nanoparticles, more sensitive imaging contrast 
agents can be obtained for their use with different imaging techniques. 
Recently, great attention has been attracted by nanoparticles that can act as 
contrast agents for several imaging techniques simultaneously. At the same 
time, nanoparticles can constitute powerful tools for the treatment of those 
same diseases, either by their own intrinsic characteristics, or by using them as 
carriers of different drugs. It is worth noting that, for each particular application, 
the pathological characteristics of the diseased tissues and cells have to be 
taken into account.  
The evolution of the field of nanomedicine in the last decades holds great 
promise, and their use could revolutionize the practice of medicine in a wide 
variety of clinical situations. However, before that can happen, all of the 
problems of current strategies have to be carefully addressed by the 
nanomedicine scientific community. 
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